Latest news with #DevangshuDatta
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Analysts split on Tech Mahindra's outlook despite margin, deal growth
Tech Mahindra's Q1FY26 profit up 33% YoY and deal wins rise 44% but analysts offer mixed views on growth prospects; stock down 3% on cautious outlook Devangshu Datta Listen to This Article Tech Mahindra reported revenue of Rs 13,350 crore for the April–June quarter (Q1) of FY26, representing a decline of 1.4 per cent quarter-on-quarter (QoQ) and 1.0 per cent year-on-year (YoY) in constant currency (CC) terms. On a sequential basis in USD terms, the Communications vertical was up 2.8 per cent QoQ, BFSI (banking, financial services and insurance) was down 0.6 per cent, Manufacturing up 4.0 per cent, Hi-tech & Media up 1.3 per cent, Retail, Transport & Logistics down 1.0 per cent, and Healthcare up 0.1 per cent QoQ. Geography-wise, the Americas were up 2.6 per cent QoQ, Europe up
&w=3840&q=100)
Business Standard
11-07-2025
- Business
- Business Standard
Near-term upside from deal with AbbVie may be priced in Glenmark's stock
Glenmark's $700 million deal with AbbVie for ISB-2001 could unlock significant upside, though analysts note the potential is already priced in, with stock surging post-announcement premium Devangshu Datta Listen to This Article Glenmark Pharma (GNP) has just signed an exclusive licensing deal with AbbVie through its subsidiary, Ichnos Glenmark Innovation (IGI), for its lead investigational asset, ISB-2001. The deal could be transformative as it leverages IGI's BEAT protein platform for oncology and autoimmune diseases and the potential of ISB-2001 to treat relapsed and refractory multiple myelomas, underlining the commercial viability of ISB-2001 following successful clinical trials. AbbVie is considered a diversified biopharma leader. In oncology, it has built a robust presence anchored by cornerstone therapies, which have improved the treatment for chronic lymphocytic leukaemia and other B-cell malignancies, generating multi-billion-dollar
&w=3840&q=100)
Business Standard
03-07-2025
- Business
- Business Standard
Competitive and margin pressures likely to cap upsides for DMart
DMart's Q1FY26 pre-quarter update reveals slower-than-expected revenue growth and margin compression. Competitive pressures, particularly from quick commerce players, could weigh on future growth. Devangshu Datta Mumbai Listen to This Article The Street reacted negatively to Avenue Supermarts' (DMart) Q1FY26 pre-quarter update, with the stock down over 1 per cent at close. The standalone revenue of Rs 15,930 crore was up 16.2 per cent year-on-year (Y-o-Y) but was below analysts' estimates. On a quarter-on-quarter (Q-o-Q) basis, growth was 10.2 per cent. Net store additions stood at nine in the quarter, versus six in Q1FY25 and 28 in Q4FY25. The total store count reached 424. The same-store growth rate was around 3-4 per cent, while the implied or estimated operating profit margin was just below 8 per cent, compared to 8.7 per
&w=3840&q=100)
Business Standard
01-07-2025
- Business
- Business Standard
Strong growth will keep valuations at elevated levels for EMS majors
EMS sector expected to grow 25% annually till FY28 as order books expand and capex ramps up; high-margin orders and policy support sustain premium valuations Devangshu Datta Listen to This Article The EMS (Electronic Manufacturing Services) sector is riding on structural growth drivers. These include supportive policies and strong demand across sectors such as automotive, industrial, consumer durables, energy, defence, medical, infrastructure, and others. Apart from the large domestic market, the China-plus strategy is boosting exports. This is a competitive market characterised by low margins and high volumes. EMS in India is expected to reach Rs 27.7 trillion by FY28, implying over 25 per cent annual growth between FY23 and FY28, when it was valued at Rs 8.4 trillion.
&w=3840&q=100)
Business Standard
23-06-2025
- Business
- Business Standard
Sustained high crude oil prices to hurt downstream players
The fears centre around the possibility of supply routes being interdicted and hence, supply being disrupted, rather than Iranian oil being taken off the market Devangshu Datta New Delhi Listen to This Article The Iran-Israel conflict entered a more intense phase with the US carrying out airstrikes on Iran's nuclear facilities over the weekend. The heightened tensions have led to further spikes in crude prices with Brent crossing the $81 per barrel or bbl mark. The fears centre around the possibility of supply routes being interdicted and hence, supply being disrupted, rather than Iranian oil being taken off the market. Iran's exports are mainly to China and the quantum of Iranian exports could be compensated for by Saudi Arabia and other OPEC-plus nations. Net-net, even with Iranian supply off the market, there could
